A dataset of molecular classification of endometrial cancer of Chinese Population, China 2020–2021

Endometrial cancer patients diagnosed and treated in Peking University People’s Hospital (PKUPH, Beijing, China) from January 2020 to December 2021 were consecutively included in this study. With our center (PKUPH) being a major referral center, the patients included were from different provinces of China, including those initially diagnosed and treated in our center and those diagnosed in local hospitals and then referred to our center. Of the 240 patients diagnosed with newly diagnosed ECs at PKUPH from January 2020 to December 2021, 229 patients whose pathology was confirmed as EEC or SEC by histology were retrospectively analyzed. Formalin-fixed paraffin-embedded (FFPE) tissue was collected from the 229 EC patients. Clinical information obtained from hospital records included age at diagnosis, surgical stage, and disease status. The patients were staged according to the International Federation of Gynecology and Obstetrics criteria. Tumor grade, histologic subtype, depth of myometrial invasion, and lymphovascular invasion were reviewed by a gynecologic pathologist based on the 2020 World Health Organization criteria. All ECs in this dataset were classified in one of the four molecular subgroups according a modified TCGA classification (TransPROTECT).